Emergent BioSolutions (EBS) Amortization of Goodwill (2022 - 2023)
Emergent BioSolutions' (EBS) quarterly Amortization of Goodwill came in at $218.2 million in Q3 2023, up 3156.72% quarter-over-quarter from $6.7 million in Q4 2022.
Emergent BioSolutions (EBS) Amortization of Goodwill (2022 - 2023) Analysis & Trends
Emergent BioSolutions' Amortization of Goodwill history runs 2 years deep, the most recent figure standing at $218.2 million for Q3 2023.
- On a quarterly basis, Amortization of Goodwill changed N/A year-over-year to $218.2 million in Q3 2023; TTM through Dec 2024 was $224.9 million, a N/A change from a year earlier, with the FY2023 full-year figure at $218.2 million, up 3156.72% from the prior year.
- Amortization of Goodwill improved to $218.2 million in Q3 2023 per EBS's latest filing, from $6.7 million in the prior quarter.
- Across five years, Amortization of Goodwill topped out at $218.2 million in Q3 2023 and bottomed at $6.7 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 218.20 Mn |
| Sep 30, 2023 | 218.20 Mn |
| Dec 31, 2022 | 6.70 Mn |
| Dec 31, 2022 | 6.70 Mn |